Hollencrest Capital Management’s Definium Therapeutics DFTX Stock Holding History

Hollencrest Capital Management’s Portfolio DFTX Stock Details DFTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$11.1K	Sell	236 -7,150	-97%	-$177K	﹤0.01%	808
2026 Q1	$140K	Sell	7,386 -130	-2%	-$2.21K	0.01%	364
2025 Q4	$101K	Hold	7,516	–	–	﹤0.01%	446
2025 Q3	$88.6K	Buy	7,516 +300	+4%	+$2.8K	﹤0.01%	459
2025 Q2	$46.8K	Hold	7,216	–	–	﹤0.01%	528
2025 Q1	$42.2K	Hold	7,216	–	–	﹤0.01%	550
2024 Q4	$50.2K	Buy	7,216 +7,150	+10,833%	+$49.2K	﹤0.01%	534
2024 Q3	$376	Hold	66	–	–	﹤0.01%	1053
2024 Q2	$476	Hold	66	–	–	﹤0.01%	1025
2024 Q1	$620	Hold	66	–	–	﹤0.01%	990
2023 Q4	$242	Hold	66	–	–	﹤0.01%	997
2023 Q3	$207	Hold	66	–	–	﹤0.01%	1028
2023 Q2	$236	Hold	66	–	–	﹤0.01%	1075
2023 Q1	$209	Hold	66	–	–	﹤0.01%	1093
2022 Q4	$145	Buy	+66	New	+$183	﹤0.01%	1101

Other funds holding DFTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Hollencrest Capital Management's DFTX Position: Q2 2026 in Review

Hollencrest Capital Management reduced its Definium Therapeutics (DFTX) stake by 97% in Q2 2026, selling an estimated $177K and leaving 236 shares worth $11.1K. The position accounts for ﹤0.01% of the portfolio, ranked #808.

Hollencrest Capital Management first reported a position in DFTX in Q4 2022 and has held it in 15 quarters since. The position peaked at $140K in Q1 2026. 362 funds tracked by Wall St. Rank hold DFTX as of Q2 2026.

Hollencrest Capital Management held 236 shares of Definium Therapeutics worth $11.1K as of Q2 2026.
Hollencrest Capital Management sold 7,150 Definium Therapeutics shares in Q2 2026, an estimated $177K.
Definium Therapeutics made up ﹤0.01% of Hollencrest Capital Management's portfolio in Q2 2026, its #808 holding.
Hollencrest Capital Management first reported a position in Definium Therapeutics in Q4 2022 and has held it in 15 quarters since.
Hollencrest Capital Management's Definium Therapeutics position peaked at $140K in Q1 2026.
362 funds tracked by Wall St. Rank held Definium Therapeutics as of Q2 2026.

Based on Hollencrest Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.